Ajanta Pharma is renowned in the pharmaceutical industry for its unwavering dedication to providing high-quality medicines to over 30 countries worldwide. The company has attained leadership positions in various molecules and therapeutic segments by introducing pioneering first-to-market products and prioritizing customer-centric approaches. Its business model encompasses Branded Generics in India and Emerging Markets, Generics in the USA, and Institution Sales in Africa, ensuring both scalability and sustainability. Ajanta Pharma’s relentless commitment to meeting patient needs drives its development of differentiated first-to-market products, further solidifying its position in various therapeutic segments. Operating state-of-the-art manufacturing facilities in India with stringent quality standards approved by regulatory authorities, the company has earned a reputation for trust and reliability among healthcare professionals and patients globally. With a strong focus on research and development and a diverse workforce exceeding 7,700 individuals from various nationalities, Ajanta Pharma remains steadfast in its mission to serve global healthcare needs through empathy and innovation.
Ajanta Pharma Reports Strong Q4 Results
- Ajanta Pharmaceuticals announced its Q4 results on May 2, 2024, with a remarkable 65.82% year-on-year increase in profit.
- Despite a 4.62% decline in revenue from the previous quarter, the company achieved robust top-line growth of 19.53%.
- Selling, general & administrative expenses witnessed a slight 0.93% quarter-on-quarter increase and a 4.41% year-on-year rise.
- Operating income showed a mixed performance, declining by 15.07% quarter-on-quarter but surging by an impressive 50.12% year-on-year.
- The earnings per share (EPS) for Q4 stood at ₹16.09, marking a notable 68.63% year-on-year rise.
- Ajanta Pharmaceuticals reported positive returns of 4.7% in the last week, 22.16% in the last six months, and 7.22% year-to-date.
- The company’s market capitalization is ₹28129.56 Cr, with a 52-week high/low of ₹2353.95 & ₹1235.89 respectively.
Below are the trading platforms that you can use to purchase Ajanta Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| May 2024 | 2,429.54 | 2,112.64 |
| June 2024 | 2,517.00 | 2,188.70 |
| July 2024 | 2,491.83 | 2,166.81 |
| August 2024 | 2,591.50 | 2,253.48 |
| September 2024 | 2,695.16 | 2,343.62 |
| October 2024 | 2,642.32 | 2,297.67 |
| November 2024 | 2,748.01 | 2,389.57 |
| December 2024 | 2,775.49 | 2,413.47 |
In May 2024, Ajanta Pharma’s shares are projected to reach a maximum price of ₹2,429.54 and a minimum price of ₹2,112.64, indicating potential fluctuations within this range. As we progress into June, prices are anticipated to rise, with the maximum and minimum prices forecasted at ₹2,517.00 and ₹2,188.70, respectively. July’s forecast suggests relatively stable prices, with Ajanta Pharma’s shares trading between ₹2,491.83 (minimum) and ₹2,166.81 (maximum). Throughout the year, Ajanta Pharma’s stock prices exhibit fluctuations, peaking at ₹2,775.49 in December and reaching a minimum of ₹2,413.47 by December 2024.
| When | Maximum Price | Minimum Price |
| January 2025 | 2,803.25 | 2,156.34 |
| February 2025 | 2,831.56 | 2,178.12 |
| March 2025 | 2,891.02 | 2,223.86 |
| April 2025 | 2,862.40 | 2,201.85 |
| May 2025 | 2,779.03 | 2,137.71 |
| June 2025 | 2,904.08 | 2,233.91 |
| July 2025 | 2,847.14 | 2,190.11 |
| August 2025 | 2,935.20 | 2,257.84 |
| September 2025 | 2,970.42 | 2,284.94 |
| October 2025 | 3,047.65 | 2,344.35 |
| November 2025 | 3,123.84 | 2,402.96 |
| December 2025 | 3,264.42 | 2,511.09 |
As we step into January 2025, Ajanta Pharma’s shares are poised to trade within a range of ₹2,803.25 to ₹2,156.34, reflecting potential market movements and investor sentiment. Moving forward to February, a slight uptick is expected, with prices projected between ₹2,831.56 and ₹2,178.12, indicating a positive momentum in the company’s stock performance. By March, Ajanta Pharma’s shares are anticipated to continue their upward trajectory, trading within the range of ₹2,891.02 to ₹2,223.86, reflecting growing confidence in the company’s financial outlook. This positive trend persists throughout the year, with December 2025 witnessing prices ranging from ₹3,264.42 to ₹2,511.09.
| When | Maximum Price | Minimum Price |
| January 2026 | 3,362.35 | 2,586.42 |
| February 2026 | 3,278.29 | 2,521.76 |
| March 2026 | 3,343.85 | 2,572.20 |
| April 2026 | 3,412.10 | 2,624.69 |
| May 2026 | 3,378.31 | 2,598.70 |
| June 2026 | 3,462.77 | 2,663.67 |
| July 2026 | 3,394.87 | 2,611.44 |
| August 2026 | 3,499.87 | 2,692.21 |
| September 2026 | 3,569.87 | 2,746.05 |
| October 2026 | 3,662.68 | 2,817.45 |
| November 2026 | 3,754.25 | 2,887.89 |
| December 2026 | 3,848.11 | 2,960.08 |
| When | Maximum Price | Minimum Price |
| January 2027 | 3,886.59 | 2,989.68 |
| February 2027 | 3,986.24 | 3,066.34 |
| March 2027 | 4,141.71 | 3,185.93 |
| April 2027 | 4,060.50 | 3,123.46 |
| May 2027 | 3,942.23 | 3,032.49 |
| June 2027 | 4,119.63 | 3,168.95 |
| July 2027 | 4,038.85 | 3,106.81 |
| August 2027 | 4,163.77 | 3,202.90 |
| September 2027 | 4,309.50 | 3,315.00 |
| October 2027 | 4,421.55 | 3,401.19 |
| November 2027 | 4,532.09 | 3,486.22 |
| December 2027 | 4,645.39 | 3,573.37 |
| When | Maximum Price | Minimum Price |
| January 2028 | 4,738.30 | 3,644.84 |
| February 2028 | 4,859.79 | 3,738.30 |
| March 2028 | 5,049.32 | 3,884.09 |
| April 2028 | 4,950.32 | 3,807.93 |
| May 2028 | 4,806.13 | 3,697.02 |
| June 2028 | 5,022.41 | 3,863.39 |
| July 2028 | 4,923.93 | 3,787.64 |
| August 2028 | 5,076.22 | 3,904.78 |
| September 2028 | 5,253.88 | 4,041.45 |
| October 2028 | 5,390.48 | 4,146.53 |
| November 2028 | 5,525.25 | 4,250.19 |
| December 2028 | 5,663.38 | 4,356.44 |
| When | Maximum Price | Minimum Price |
| January 2029 | 5,776.64 | 4,443.57 |
| February 2029 | 5,924.76 | 4,557.51 |
| March 2029 | 6,155.83 | 4,735.25 |
| April 2029 | 6,035.13 | 4,642.41 |
| May 2029 | 5,859.35 | 4,507.19 |
| June 2029 | 6,123.02 | 4,710.01 |
| July 2029 | 6,002.96 | 4,617.66 |
| August 2029 | 6,188.62 | 4,760.47 |
| September 2029 | 6,405.22 | 4,927.09 |
| October 2029 | 6,571.75 | 5,055.20 |
| November 2029 | 6,736.05 | 5,181.58 |
| December 2029 | 6,904.45 | 5,311.11 |
| When | Maximum Price | Minimum Price |
| January 2030 | 7,042.54 | 5,417.34 |
| February 2030 | 7,223.12 | 5,556.24 |
| March 2030 | 7,504.82 | 5,772.94 |
| April 2030 | 7,357.66 | 5,659.74 |
| May 2030 | 7,143.36 | 5,494.89 |
| June 2030 | 7,464.81 | 5,742.16 |
| July 2030 | 7,318.45 | 5,629.57 |
| August 2030 | 7,544.79 | 5,803.68 |
| September 2030 | 7,808.86 | 6,006.81 |
| October 2030 | 8,011.89 | 6,162.99 |
| November 2030 | 8,212.18 | 6,317.06 |
| December 2030 | 8,417.49 | 6,474.99 |
As we look ahead to January 2030, Ajanta Pharma’s shares are forecasted to trade between a maximum price of ₹7,042.54 and a minimum price of ₹5,417.34, suggesting potential market fluctuations and investor sentiment at the beginning of the year. Moving into December, the company’s shares are anticipated to reach their peak, with prices projected to range from ₹8,417.49 (maximum) to ₹6,474.99 (minimum), reflecting sustained investor interest and optimism in Ajanta Pharma’s future growth prospects throughout 2030.
Ajanta Pharma Financial Condition
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 |
| Expenses + | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 |
| Operating Profit | 683 | 1,001 | 933 | 808 | 1,172 |
| OPM % | 26% | 35% | 28% | 22% | 28% |
| Other Income + | 88 | 24 | 112 | 74 | 85 |
| Interest | 12 | 8 | 10 | 6 | 7 |
| Depreciation | 96 | 116 | 125 | 131 | 135 |
| Profit before tax | 664 | 900 | 909 | 745 | 1,114 |
| Tax % | 30.00% | 27.00% | 22.00% | 21.00% | 27.00% |
| Net Profit + | 468 | 654 | 713 | 588 | 816 |
| EPS in Rs | 35.73 | 50.38 | 55.63 | 45.89 | 64.82 |
| Dividend Payout % | 24.00% | 13.00% | 11.00% | 15.00% | 79.00% |
Ajanta Pharma has witnessed remarkable sales growth over the past five years, climbing from ₹2,588 crores in March 2020 to ₹4,209 crores in March 2024, showcasing a consistent upward trajectory. Despite this growth, the company managed its expenses effectively in proportion to sales, ensuring healthy profit margins even amidst fluctuations. Operating profit, although fluctuating, remained robust, peaking at ₹1,172 crores in March 2024, underscoring the company’s operational efficiency. Supplementary revenue streams, including investments and non-core activities, bolstered Ajanta Pharma’s overall profitability, contributing to its sustained success. Furthermore, the company’s net profit exhibited an upward trend, reaching ₹816 crores in March 2024, indicative of effective management and operational resilience. Earnings Per Share (EPS) also witnessed consistent growth, rising from ₹35.73 in March 2020 to ₹64.82 in March 2024, thereby creating substantial value for shareholders. Additionally, the fluctuating dividend payout percentage, reaching 79.00% in March 2024, highlights Ajanta Pharma’s commitment to rewarding shareholders as profits continue to grow. Overall, Ajanta Pharma’s strong financial performance, coupled with effective cost management and consistent profitability, positions it favorably for sustained growth and value creation in the pharmaceutical industry.
BOB Capital Markets Ltd suggests investors consider acquiring shares of Ajanta Pharma, proposing a target price of ₹2585.00 for potential gains.
ICICI Direct suggests investing in Ajanta Pharma shares, setting a target price of ₹2875.00.
FAQS
As of May 6th, 2024, the share price of Ajanta Pharma is around INR ₹2,415.
Based on various market analyses and expert opinions, the expected share price target of Ajanta Pharma by 2024 is around INR 2,775.49.
It is unlikely for the share price of Ajanta Pharma to reach INR 5000 by 2025. Such a target would require a massive and unrealistic growth rate.
As per our analysis, Ajanta Pharma in 2025 is expected to trade between ₹2,137.71 and ₹3,264.42.
As per our analysis, Ajanta Pharma’s share price target for 2030 would be somewhere between ₹5,417.34 and ₹8,417.49.
ALSO READ:
- Kotak Mahindra Bank Share Price Target 2024, 2025, 2026 to 2030
- SHALIMAR PAINTS SHARE PRICE TARGET 2024, 2025, 2026 To 2030
- INDIAN OIL CORPORATION (IOC) SHARE PRICE TARGET 2024, 2025 to 2030
Conclusion
In conclusion, Ajanta Pharma’s Q4 results underscore its unwavering commitment to excellence and resilience in the pharmaceutical industry. With a significant 65.82% year-on-year increase in profit, the company demonstrates its ability to deliver strong financial performance. Despite a slight decline in revenue from the previous quarter, Ajanta Pharma achieved robust top-line growth of 19.53%. Moreover, the company’s focus on effective cost management is evident in the slight increase in selling, general & administrative expenses, which were effectively managed relative to sales growth. These results reflect Ajanta Pharma’s dedication to operational efficiency and sustainable growth, positioning it as a leader in the global healthcare market.
However, it’s important to note that we are not financial advisors. Please consult with a SEBI-registered financial advisor before making any investment decisions regarding Ajanta Pharma. This discussion on Ajanta Pharma’s share price target from 2024 to 2030 is provided for educational purposes only.
What did we learn?
- 1 Ajanta Pharma Reports Strong Q4 Results
- 2 How to Purchase Ajanta Pharma Shares?
- 3 Ajanta Pharma Share Price Prediction 2024, 2025 to 2030
- 3.1 Ajanta Pharma Share Price Prediction 2024
- 3.2 Ajanta Pharma Share Price Prediction 2025
- 3.3 Ajanta Pharma Share Price Target 2026
- 3.4 Ajanta Pharma Share Price Prediction 2027
- 3.5 Ajanta Pharma Share Price Target 2028
- 3.6 Ajanta Pharma Share Price Prediction 2029
- 3.7 Ajanta Pharma Share Price Target 2030
- 4 Ajanta Pharma Financial Condition
- 5 Ajanta Pharma’s Share Price Target by Experts
- 6 FAQS
- 7 Conclusion
